- Conditions
- Breast Cancer
- Interventions
- Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 393
- States / cities
- Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 7,881
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, sargramostim, tetanus peptide melanoma vaccine
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 65
- States / cities
- Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 23
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
- Interventions
- Radiation Therapy, Temozolomide, Veliparib
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Second Sight Medical Products
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
- Conditions
- Cigarette Smoking
- Interventions
- urine analyses feedback
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- ALD (Adrenoleukodystrophy), Adrenoleukodystrophy, Cerebral Adrenoleukodystrophy
- Interventions
- Medical Record Abstraction, Biospecimen Sample Collection
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer, Metastases
- Interventions
- Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
- Drug · Radiation · Other
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
- Interventions
- Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
- Conditions
- Hemophilia B
- Interventions
- IB1001, nonacog alfa
- Biological
- Lead sponsor
- Medexus Pharma, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Migraine, With or Without Aura
- Interventions
- Ubrogepant, Placebo-matching Ubrogepant, Usual Care
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 1,254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 177
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2011
- U.S. locations
- 205
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 162
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 114 more
- Conditions
- AAA - Abdominal Aortic Aneurysm
- Interventions
- Not listed
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 44
- States / cities
- Little Rock, Arkansas • Irvine, California • Los Angeles, California + 38 more
- Conditions
- Stress Urinary Incontinence
- Interventions
- AMS 800
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
- Interventions
- Blue Light Therapy, Sham Light Therapy
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Parkinson, Parkinson Disease
- Interventions
- Neuroimaging, Quantitative assessments
- Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lymphoma
- Interventions
- denileukin diftitox, rituximab
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 165
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 104 more
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
- Procedure · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 883
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
- Conditions
- Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma, Medulloepithelioma, Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Germ Cell Tumor, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
- Interventions
- Carboplatin, Mannitol, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Portland, Oregon
- Conditions
- OCD
- Interventions
- Sertraline, No Intervention
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Oral Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Osteopetrosis
- Interventions
- Interferon gamma-1b
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Torrance, California • Minneapolis, Minnesota
- Conditions
- Hemophilia
- Interventions
- Coagulation Factor VIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more